• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

AJMC® in the Press, January 29, 2021

Article

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

An article by Becker's Spine Review referenced a study published in the October 2020 issue of The American Journal of Managed Care® (AJMC®). The study, “Successes and Failures With Bundled Payments in the Commercial Market,” indicated that while Medicare has embraced condition-specific bundled payments in its Bundled Payments for Care Improvement initiatives, commercial insurers have been slow to follow Medicare’s lead. As the authors note, successful plans have closely aligned providers and payers who share data seamlessly.

A press release by Ken Research cited an article published by AJMC®’s sister site The Center for Biosimilars®, titled “As Patents Expire, Oncology Biosimilars Poised to Expand, Authors Say.” The article noted that by 2023, patents on nearly 20 oncology biologics will expire, which could lead to more biosimilars in cancer care and therefore reduced costs.

A piece by TulsaPeople Magazine spotlighted an article published on AJMC.com, the website of AJMC®. The article, “Cancer Care Delays in COVID-19 Could Lead to Higher Morbidity, Mortality,” indicated that screening and treatments for breast, colon, prostate, and lung cancers saw significant declines in 2020 due to the coronavirus disease 2019 pandemic, with oncology care delivery still yet to fully rebound.

Related Videos
Leslie Fish, PharmD.
Mila Felder, MD, FACEP
Shawn Gremminger
Dr Lucy Langer
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr David Fajgenbaum | Image credit: The Castleman Disease Collaborative Network
Takiyah Durham, MBA, and Margaret Larkins-Pettigrew, MD
Takiyah Durham, MBA, Margaret Larkins-Pettigrew, MD
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.